GB9105992D0
(en)
*
|
1991-03-21 |
1991-05-08 |
Smithkline Beecham Biolog |
Vaccine
|
CZ282235B6
(cs)
*
|
1992-06-25 |
1997-06-11 |
Smithkline Beecham Biologicals (S.A.) |
Očkovací prostředek, jeho použití k výrobě vakcíny, způsob léčby patogenních infekcí tímto prostředkem a způsob jeho výroby
|
WO1994019013A1
(en)
*
|
1993-02-19 |
1994-09-01 |
Smithkline Beecham Corporation |
Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
|
US5773011A
(en)
*
|
1993-09-27 |
1998-06-30 |
Gerbu Biotechnik Gmbh |
Method of preparing a synergistic immunological adjuvant formulation
|
US6083513A
(en)
*
|
1993-11-16 |
2000-07-04 |
Gerbu Biotechnik Gmbh |
Method for increasing the yield of antibodies in the techniques of immunology
|
GB9326253D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
AUPM446594A0
(en)
*
|
1994-03-16 |
1994-04-14 |
Csl Limited |
Cytotoxic t-cell epitopes identified within epstein-barr virus
|
GB9506863D0
(en)
*
|
1995-04-03 |
1995-05-24 |
Smithkline Beecham Biolog |
Vaccines
|
US6846489B1
(en)
*
|
1995-04-25 |
2005-01-25 |
Smithkline Beecham Biologicals S.A. |
Vaccines containing a saponin and a sterol
|
US20010053365A1
(en)
*
|
1995-04-25 |
2001-12-20 |
Smithkline Beecham Biologicals S.A. |
Vaccines
|
UA56132C2
(uk)
*
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
GB9513261D0
(en)
*
|
1995-06-29 |
1995-09-06 |
Smithkline Beecham Biolog |
Vaccines
|
EP0909323B1
(en)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Helicobacter pylori bacterioferritin
|
US7112331B2
(en)
|
1996-02-09 |
2006-09-26 |
Smithkline Beecham Biologicals, S.A. |
Vaccines against varicella zoster virus gene 63 product
|
GB9616351D0
(en)
*
|
1996-08-02 |
1996-09-11 |
Smithkline Beecham Biolog |
Vaccine composition
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
GB9706957D0
(en)
*
|
1997-04-05 |
1997-05-21 |
Smithkline Beecham Plc |
Formulation
|
US6080725A
(en)
*
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
JP4583511B2
(ja)
*
|
1997-05-20 |
2010-11-17 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
アジュバントおよび免疫刺激活性を有するトリテルペンサポニンアナログ
|
GB9712347D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
US7459524B1
(en)
*
|
1997-10-02 |
2008-12-02 |
Emergent Product Development Gaithersburg Inc. |
Chlamydia protein, sequence and uses thereof
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
CN1227360C
(zh)
|
1998-02-05 |
2005-11-16 |
史密丝克莱恩比彻姆生物有限公司 |
Mage家族肿瘤相关抗原衍生物及其编码核酸序列
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
JP4227302B2
(ja)
|
1998-04-07 |
2009-02-18 |
コリクサ コーポレイション |
Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
KR20060118628A
(ko)
*
|
1998-04-29 |
2006-11-23 |
와이어쓰 홀딩스 코포레이션 |
나이제리아 고노리아 또는 나이제리아 메닌지티디스에 대한재조합 필린을 함유한 백신
|
US6306404B1
(en)
|
1998-07-14 |
2001-10-23 |
American Cyanamid Company |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
JP2002522451A
(ja)
|
1998-08-07 |
2002-07-23 |
ユニバーシティ オブ ワシントン |
免疫学的単純ヘルペスウイルス抗原とその使用法
|
AU5565599A
(en)
|
1998-08-14 |
2000-03-06 |
Dante J. Marciani |
Chemically modified saponins and the use thereof as adjuvants
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
GB9820525D0
(en)
*
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
SI1126876T1
(sl)
*
|
1998-10-16 |
2007-08-31 |
Glaxosmithkline Biolog Sa |
Adjuvantni sistemi in vakcine
|
GB9826886D0
(en)
*
|
1998-12-07 |
1999-01-27 |
Smithkline Beecham Biolog |
Novel compounds
|
EP1144642B1
(en)
|
1998-12-08 |
2010-05-26 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US20020061848A1
(en)
*
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US6706270B1
(en)
|
1998-12-08 |
2004-03-16 |
Smithkline Beecham Biologicals S.A. |
Compounds
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
CA2365102A1
(en)
|
1999-03-12 |
2000-09-21 |
Smithkline Beecham Biologicals S.A. |
Neisseria meningitidis antigenic polypeptides and encoding polynucleotides and uses thereof
|
GB9909077D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
DE60038166T2
(de)
|
1999-03-19 |
2009-03-12 |
Glaxosmithkline Biologicals S.A., Rixensart |
Impfstoff gegen bakterielle antigene
|
WO2000061612A2
(en)
|
1999-04-02 |
2000-10-19 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
HU229255B1
(en)
|
1999-04-19 |
2013-10-28 |
Smithkline Beecham Biolog |
Vaccines
|
US6635261B2
(en)
|
1999-07-13 |
2003-10-21 |
Wyeth Holdings Corporation |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9919468D0
(en)
|
1999-08-17 |
1999-10-20 |
Smithkline Beecham Biolog |
Vaccine
|
CA2388337C
(en)
|
1999-10-22 |
2013-01-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
GB0000891D0
(en)
*
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
DZ3286A1
(fr)
*
|
2000-01-31 |
2001-08-02 |
Smithkline Beecham Biologicals |
Nouvelle utilisation
|
AU5615601A
(en)
|
2000-02-23 |
2001-09-03 |
Smithkline Beecham Biolog |
Novel compounds
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
EP2192128A3
(en)
|
2000-04-21 |
2010-09-22 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US6919187B2
(en)
*
|
2000-04-21 |
2005-07-19 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
CA2408328C
(en)
|
2000-05-10 |
2012-04-17 |
Aventis Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
ATE442866T1
(de)
|
2000-06-20 |
2009-10-15 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
BR122012003821B8
(pt)
|
2000-06-29 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
composição imunogênica multivalente, uso da mesma, e, processo para produzir a composição imunogênica
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
SI2266603T1
(sl)
|
2000-10-18 |
2012-12-31 |
Glaxosmithkline Biologicals S.A. |
Tumorska cepiva
|
EP1201250A1
(en)
*
|
2000-10-25 |
2002-05-02 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Immunogenic compositions comprising liver stage malarial antigens
|
NZ524888A
(en)
|
2000-10-27 |
2006-09-29 |
Chiron S |
Nucleic acids and proteins from streptococcus groups A & B
|
US6892140B1
(en)
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
WO2002046477A2
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
EP2269639B1
(en)
|
2001-02-23 |
2018-11-28 |
GlaxoSmithKline Biologicals s.a. |
Influenza vaccine formulations for intradermal delivery
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20020193295A1
(en)
*
|
2001-05-04 |
2002-12-19 |
Emanuel Calenoff |
Immunogenic peptides and uses thereof
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
WO2003005952A2
(en)
|
2001-07-10 |
2003-01-23 |
Corixa Corporation |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
GB0118367D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxosmithkline Biolog Sa |
Novel use
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
ES2607431T3
(es)
|
2002-02-20 |
2017-03-31 |
Glaxosmithkline Biologicals Sa |
Micropartículas con moléculas que contienen polipéptidos adsorbidos
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
EP2330113B1
(en)
|
2002-04-19 |
2016-06-29 |
The Governing Council Of The University Of Toronto |
Immunological methods and compositions for the treatment of Alzheimer's disease
|
EP1532161B1
(en)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vectors for expression of hml-2 polypeptides
|
EP2011510B1
(en)
|
2002-07-18 |
2011-01-12 |
University of Washington |
Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
|
TWI360424B
(en)
|
2002-08-02 |
2012-03-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
PT1549338E
(pt)
|
2002-10-11 |
2011-02-23 |
Novartis Vaccines & Diagnostic |
Vacinas polipeptídicas para protecção alargada contra linhagens meningocócicas hipervirulentas
|
NZ539509A
(en)
|
2002-10-23 |
2008-05-30 |
Glaxosmithkline Biolog Sa |
Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
|
DK2279746T3
(da)
|
2002-11-15 |
2013-11-25 |
Novartis Vaccines & Diagnostic |
Overfladeproteiner i neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004061423A2
(en)
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
PT1587537E
(pt)
|
2003-01-30 |
2012-05-30 |
Novartis Ag |
Vacinas injetáveis contra múltiplos serogrupos meningocócicos
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
DE602004022286D1
(de)
|
2003-06-02 |
2009-09-10 |
Novartis Vaccines & Diagnostic |
Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
KR20060126917A
(ko)
|
2003-09-02 |
2006-12-11 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
ES2346314T3
(es)
|
2003-10-02 |
2010-10-14 |
Glaxosmithkline Biolog Sa |
Antigenos de b. pertussis y uso de los mismos en vacunacion.
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
PL1670506T3
(pl)
|
2003-10-02 |
2013-04-30 |
Novartis Ag |
Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
|
GB0323965D0
(en)
*
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
CA2551560A1
(en)
|
2003-12-23 |
2005-07-14 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of hpv and methods of their use
|
WO2005076972A2
(en)
|
2004-02-05 |
2005-08-25 |
The Ohio State University Research Foundation |
Chimeric vegf peptides
|
US20080254065A1
(en)
|
2004-03-09 |
2008-10-16 |
Chiron Corporation |
Influenza Virus Vaccines
|
RU2379052C2
(ru)
|
2004-04-30 |
2010-01-20 |
Чирон С.Р.Л. |
Вакцинация менингококковыми конъюгатами
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP1766034B1
(en)
|
2004-05-21 |
2014-03-19 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
GB0411411D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Glaxosmithkline Biolog Sa |
Vaccines
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
JP2008500984A
(ja)
|
2004-05-28 |
2008-01-17 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ヴィロソームとサポニンアジュバントを含むワクチン組成物
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0420634D0
(en)
*
|
2004-09-16 |
2004-10-20 |
Glaxosmithkline Biolog Sa |
Vaccines
|
BR122016029840B1
(pt)
|
2004-09-22 |
2021-10-13 |
Glaxosmithkline Biologicals S.A. |
Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
|
US8846051B2
(en)
|
2004-10-08 |
2014-09-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by deoptimization of synonymous codons
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
LT2682126T
(lt)
|
2005-01-27 |
2017-02-27 |
Children`s Hospital & Research Center at Oakland |
Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
ES2385045T3
(es)
|
2005-02-18 |
2012-07-17 |
Novartis Vaccines And Diagnostics, Inc. |
Inmunógenos de Escherichia coli uropatogénica
|
US8758764B2
(en)
|
2005-02-18 |
2014-06-24 |
Novartis Vaccines And Diagnostics Srl |
Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
|
GB0504436D0
(en)
*
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006104890A2
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
PL2457926T3
(pl)
|
2005-04-29 |
2015-03-31 |
Glaxosmithkline Biologicals Sa |
Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
|
AU2006261342B2
(en)
|
2005-06-15 |
2012-02-02 |
The Ohio State University Research Foundation |
Her-2 peptides
|
GB0513421D0
(en)
*
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
WO2007005627A2
(en)
|
2005-07-01 |
2007-01-11 |
Forsyth Dental Infirmary For Children |
Tuberculosis antigen detection assays and vaccines
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
CA2628424A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
EP2377552A3
(en)
|
2005-11-04 |
2013-05-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Influenza vaccines with reduced amount of emulsion adjuvant
|
PL2368572T3
(pl)
|
2005-11-04 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
|
WO2007052061A2
(en)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101378779B
(zh)
|
2005-12-22 |
2015-09-02 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗
|
EP1965856A2
(en)
|
2005-12-30 |
2008-09-10 |
Tti Ellebeau, Inc. |
Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
NZ569417A
(en)
|
2006-01-17 |
2012-04-27 |
Arne Forsgren |
A novel surface exposed haemophilus influenzae protein (protein E; pE)
|
KR20080089663A
(ko)
|
2006-01-27 |
2008-10-07 |
노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 |
적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
|
ES2388556T3
(es)
|
2006-03-23 |
2012-10-16 |
Novartis Ag |
Compuestos inmunopotenciadores
|
EP2010537B1
(en)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
CA2647441C
(en)
|
2006-03-30 |
2021-02-23 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition comprising staphylococcus aureus saccharides
|
US20070243212A1
(en)
|
2006-03-30 |
2007-10-18 |
Embrex, Inc. |
Methods and compositions for vaccination of poultry
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
EP2392673A1
(en)
|
2006-06-02 |
2011-12-07 |
GlaxoSmithKline Biologicals S.A. |
Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FOXP3 gene
|
WO2008020335A2
(en)
|
2006-06-09 |
2008-02-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
JP5275983B2
(ja)
|
2006-06-12 |
2013-08-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
CA2657279A1
(en)
|
2006-07-18 |
2008-01-24 |
Glaxosmithkline Biologicals S.A. |
Vaccines for malaria
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2040744B1
(en)
|
2006-07-25 |
2016-03-09 |
The Secretary of State for Defence |
Live vaccine strains of francisella
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
WO2008091398A2
(en)
*
|
2006-08-31 |
2008-07-31 |
Baylor Research Institute |
Jc virus vaccine
|
CA2662064A1
(en)
|
2006-09-07 |
2008-03-13 |
Glaxosmithkline Biologicals S.A. |
Method of producing a combination polivirus vaccine
|
CA2663196A1
(en)
|
2006-09-11 |
2008-03-20 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
ES2673046T3
(es)
|
2006-09-26 |
2018-06-19 |
Infectious Disease Research Institute |
Composición de vacuna que contiene un adyuvante sintético
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
MX2009009342A
(es)
|
2007-03-02 |
2009-09-11 |
Glaxosmithkline Biolog Sa |
Metodo novedoso y composiciones.
|
US8486414B2
(en)
|
2007-04-04 |
2013-07-16 |
Infectious Disease Research Institute |
Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
HUE026853T2
(en)
|
2007-06-26 |
2016-08-29 |
Glaxosmithkline Biologicals Sa |
Vaccine containing Streptococcus pneumoniae capsular polysaccharide conjugates
|
AU2008269439B2
(en)
|
2007-06-27 |
2013-12-19 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
CA2695399C
(en)
|
2007-08-02 |
2017-10-17 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
EP2185577A4
(en)
|
2007-08-03 |
2010-09-22 |
Harvard College |
CHLAMYDIA ANTIGENS
|
WO2009021931A1
(en)
|
2007-08-13 |
2009-02-19 |
Glaxosmithkline Biologicals S.A. |
Vaccines
|
BRPI0816689B1
(pt)
|
2007-09-12 |
2021-08-24 |
Novartis Ag |
Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
|
EP2198045A1
(en)
|
2007-09-17 |
2010-06-23 |
Oncomethylome Sciences SA |
Improved detection of mage-a expression
|
EP2045263A1
(en)
|
2007-10-02 |
2009-04-08 |
Universite Libre De Bruxelles |
Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
CA2744739A1
(en)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
ES2626634T3
(es)
|
2007-12-19 |
2017-07-25 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ601543A
(en)
|
2007-12-21 |
2013-03-28 |
Novartis Ag |
Mutant forms of streptolysin o
|
JP5711972B2
(ja)
*
|
2007-12-24 |
2015-05-07 |
アイディー バイオメディカル コーポレイション オブ ケベック |
組換えrsv抗原
|
EP2245048B1
(en)
|
2008-02-21 |
2014-12-31 |
Novartis AG |
Meningococcal fhbp polypeptides
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
WO2009127666A2
(en)
*
|
2008-04-15 |
2009-10-22 |
Glaxosmithkline Biologicals S.A. |
Method and compositions
|
CN102065880B
(zh)
|
2008-04-18 |
2015-11-25 |
综合医院公司 |
使用自我装配疫苗的免疫治疗
|
WO2009143524A2
(en)
|
2008-05-23 |
2009-11-26 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
WO2010006447A1
(en)
*
|
2008-07-18 |
2010-01-21 |
Id Biomedical Corporation Of Quebec |
Chimeric respiratory syncytial virus polypeptide antigens
|
US20110206712A1
(en)
|
2008-07-25 |
2011-08-25 |
James Brown |
Tuberculosis rv2386c protein, compositions and uses thereof
|
ES2647321T3
(es)
|
2008-07-25 |
2017-12-20 |
Glaxosmithkline Biologicals S.A. |
Composiciones y procedimientos novedosos
|
AU2009276304B2
(en)
|
2008-08-01 |
2012-10-11 |
Gamma Vaccines Pty Limited |
Influenza vaccines
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
CA2743904A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
BRPI0922132A2
(pt)
|
2008-12-03 |
2018-10-23 |
Protea Vaccine Tech Ltd |
fragmentos glutamil trna sintetase (gts).
|
KR101413844B1
(ko)
|
2008-12-09 |
2014-06-30 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
EP2385842A1
(en)
|
2009-01-12 |
2011-11-16 |
Novartis AG |
Cna_b domain antigens in vaccines against gram positive bacteria
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US8460674B2
(en)
|
2009-02-07 |
2013-06-11 |
University Of Washington |
HSV-1 epitopes and methods for using same
|
EP3173097A3
(en)
|
2009-02-10 |
2017-07-12 |
Seqirus UK Limited |
Influenza vaccines with reduced amounts of squalene
|
RU2011140508A
(ru)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Антигены хламидии
|
BRPI1009873A2
(pt)
|
2009-03-17 |
2016-03-08 |
Glaxosmithkline Biolog Sa |
detecção aperfeiçoada de expressão gênica
|
WO2010115172A2
(en)
|
2009-04-03 |
2010-10-07 |
University Of Washington |
Antigenic peptide of hsv-2 and methods for using same
|
CA3154626A1
(en)
|
2009-04-14 |
2010-10-21 |
Glaxosmithkline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
CA2757620C
(en)
|
2009-04-30 |
2016-04-26 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
CN105131051B
(zh)
|
2009-06-05 |
2020-07-10 |
传染性疾病研究院 |
合成的吡喃葡萄糖脂佐剂
|
US9526778B2
(en)
|
2009-06-15 |
2016-12-27 |
Institut Pasteur De Lille |
Influenza vaccine, composition, and methods of use
|
EP2442827B1
(en)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsion vaccines
|
US9492531B2
(en)
|
2009-06-24 |
2016-11-15 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV vaccines
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
CA2767536A1
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
BR112012001666A2
(pt)
|
2009-07-15 |
2019-09-24 |
Novartis Ag |
composições de proteína rsv f e métodos para fazer as mesmas
|
EP2464658B1
(en)
|
2009-07-16 |
2014-10-01 |
Novartis AG |
Detoxified escherichia coli immunogens
|
NZ598356A
(en)
|
2009-07-30 |
2014-06-27 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
PL2470554T3
(pl)
*
|
2009-08-26 |
2018-02-28 |
Selecta Biosciences, Inc. |
Kompozycje, które indukują pomocnicze komórki T
|
NZ622048A
(en)
|
2009-08-27 |
2015-10-30 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
ES2670576T3
(es)
|
2009-09-03 |
2018-05-31 |
Pfizer Vaccines Llc |
Vacuna de PCSK9
|
KR20120081587A
(ko)
|
2009-09-10 |
2012-07-19 |
노파르티스 아게 |
기도 질병에 대한 조합 백신
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
WO2011138636A1
(en)
|
2009-09-30 |
2011-11-10 |
Novartis Ag |
Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptídeos de modificação meningocócica fhbp"
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
MX337070B
(es)
|
2009-12-22 |
2016-02-11 |
Celldex Therapeutics Inc |
Método para preparar un conjugado klh-egfrviii.
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
EP2544713A1
(en)
|
2010-03-10 |
2013-01-16 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
CA2794558A1
(en)
|
2010-03-26 |
2011-09-29 |
Patricia Bourguignon |
Hiv vaccine
|
BR122021020829B8
(pt)
|
2010-03-30 |
2022-12-27 |
Children´S Hospital & Res Center At Oakland |
Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9744228B2
(en)
|
2010-04-07 |
2017-08-29 |
Norvartis Ag |
Method for generating a parvovirus B19 virus-like particle
|
BR112012029823A2
(pt)
|
2010-05-26 |
2020-09-01 |
Selecta Biosciences, Inc. |
seleção da dose de nanoveículos sintéticos adjuvantados
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
DK3170508T3
(da)
|
2010-06-04 |
2020-01-02 |
Wyeth Llc |
Vaccineformuleringer
|
EP2942061A3
(en)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
JP2013533745A
(ja)
|
2010-07-06 |
2013-08-29 |
ノバルティス アーゲー |
ノロウイルスに由来する免疫原性組成物および方法
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012041669A1
(en)
|
2010-09-27 |
2012-04-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
AU2011310643A1
(en)
|
2010-09-27 |
2013-04-11 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
EP2637687B1
(en)
|
2010-11-08 |
2021-01-06 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
JP6069212B2
(ja)
|
2010-12-02 |
2017-02-01 |
ビオノール イミュノ エーエスBionor Immuno As |
ペプチド骨格設計
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
AU2012204955B2
(en)
|
2011-01-06 |
2016-10-06 |
Bionor Immuno As |
Monomeric and multimeric immunogenic peptides
|
EP4144368A1
(en)
|
2011-01-26 |
2023-03-08 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
WO2012100302A1
(en)
|
2011-01-27 |
2012-08-02 |
Gamma Vaccines Pty Limited |
Combination vaccines
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
ES2716010T3
(es)
|
2011-03-29 |
2019-06-07 |
Uab Research Foundation |
Métodos y composiciones para la proteína IL-10 de citomegalovirus
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
EA027236B1
(ru)
|
2011-04-08 |
2017-07-31 |
Иммьюн Дизайн Корп. |
Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
WO2012170356A1
(en)
|
2011-06-04 |
2012-12-13 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6 of haemophilus influenzae
|
DK2691530T3
(en)
|
2011-06-10 |
2018-05-22 |
Univ Oregon Health & Science |
CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
|
US20150030586A1
(en)
|
2011-06-21 |
2015-01-29 |
Sarah Ellen Warren |
Compositions and methods for the therapy and diagnosis of cancer
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
WO2013019658A2
(en)
|
2011-07-29 |
2013-02-07 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2013038185A1
(en)
|
2011-09-12 |
2013-03-21 |
Jonathan Norden Weber |
Methods and compositions for raising an immune response to hiv
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
CN103930436A
(zh)
|
2011-09-14 |
2014-07-16 |
诺华股份有限公司 |
大肠杆菌疫苗组合
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
MX2014002769A
(es)
|
2011-09-16 |
2014-06-11 |
Ucb Pharma Sa |
Anticuerpos neutralizantes para las exotoxinas principales tcda y tcdb de clostridium difficile.
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
JP6084631B2
(ja)
|
2011-12-08 |
2017-02-22 |
ノバルティス アーゲー |
Clostridiumdifficile毒素ベースのワクチン
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
HUE044841T2
(hu)
|
2012-02-07 |
2019-11-28 |
Infectious Disease Res Inst |
TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai
|
CA2865028A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
WO2013134577A2
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen, Inc. |
Leishmaniasis antigen detection assays and vaccines
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
BR112014024612A2
(pt)
|
2012-04-02 |
2021-06-08 |
Univ North Carolina Chapel Hill |
ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
|
ES2837825T3
(es)
|
2012-04-26 |
2021-07-01 |
Glaxosmithkline Biologicals Sa |
Antígenos y combinaciones de antígenos
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
*
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
US9169304B2
(en)
|
2012-05-01 |
2015-10-27 |
Pfenex Inc. |
Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
|
EP2659907A1
(en)
*
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP3563865A3
(en)
|
2012-05-04 |
2019-12-04 |
Pfizer Inc |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
US9895435B2
(en)
|
2012-05-16 |
2018-02-20 |
Immune Design Corp. |
Vaccines for HSV-2
|
JP2015518845A
(ja)
|
2012-05-22 |
2015-07-06 |
ノバルティス アーゲー |
髄膜炎菌血清群xコンジュゲート
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
JP6310909B2
(ja)
|
2012-06-06 |
2018-04-11 |
ビオノール イミュノ エーエスBionor Immuno As |
免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
BR112015002483A2
(pt)
|
2012-08-03 |
2017-11-07 |
Infectious Disease Res Inst |
composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
US10232035B2
(en)
|
2012-09-14 |
2019-03-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes virus and use thereof in vaccines
|
WO2014044728A1
(en)
|
2012-09-18 |
2014-03-27 |
Novartis Ag |
Outer membrane vesicles
|
TR201808684T4
(tr)
|
2012-10-02 |
2018-07-23 |
Glaxosmithkline Biologicals Sa |
Lineer olmayan sakarit konjügatları.
|
EP2903638B1
(en)
|
2012-10-03 |
2019-12-18 |
GlaxoSmithKline Biologicals SA |
Immunogenic composition
|
KR101819803B1
(ko)
|
2012-10-24 |
2018-01-17 |
플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 |
혈소판 표적화 치료
|
BR112015012762A2
(pt)
|
2012-11-30 |
2017-09-12 |
Glaxosmithkline Biologicals Sa |
antígenos de pseudomonas e combinações de antígenos
|
CN112807422A
(zh)
|
2012-12-05 |
2021-05-18 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
AU2014253791B2
(en)
|
2013-04-18 |
2019-05-02 |
Immune Design Corp. |
GLA monotherapy for use in cancer treatment
|
WO2015132619A1
(en)
|
2013-05-15 |
2015-09-11 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
CA2918644A1
(en)
|
2013-06-26 |
2014-12-31 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dengue virus vaccines
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US10208102B2
(en)
|
2013-11-01 |
2019-02-19 |
University Of Oslo |
Albumin variants and uses thereof
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
WO2015103104A1
(en)
|
2014-01-06 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Attenuated salmonella enterica
|
PE20161095A1
(es)
|
2014-01-21 |
2016-10-26 |
Pfizer |
Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
EP3122380A1
(en)
*
|
2014-03-25 |
2017-02-01 |
The Government of the United States of America as represented by the Secretary of the Army |
Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
|
CN106536544B
(zh)
|
2014-06-25 |
2020-04-07 |
葛兰素史密丝克莱恩生物有限公司 |
艰难梭菌免疫原性组合物
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
AR101256A1
(es)
|
2014-07-21 |
2016-12-07 |
Sanofi Pasteur |
Composición vacunal que comprende ipv y ciclodextrinas
|
RU2714248C2
(ru)
|
2014-07-23 |
2020-02-13 |
Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд |
Варианты фактор н-связывающего белка и способы их применения
|
EP3204039B1
(en)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
MX2017005524A
(es)
|
2014-11-02 |
2018-01-26 |
Univ North Carolina Chapel Hill |
Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.
|
US20170281744A1
(en)
|
2014-12-10 |
2017-10-05 |
Glaxosmithkline Biologicals Sa |
Method of treatment
|
ES2945312T3
(es)
|
2015-01-15 |
2023-06-30 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
WO2016134300A1
(en)
|
2015-02-20 |
2016-08-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for attenuated chlamydia as vaccine and vector
|
JP2018507860A
(ja)
*
|
2015-02-26 |
2018-03-22 |
ザヴァックス ジェネティクス ワクチン カンパニー リミテッドThevax Genetics Vaccine Co., Ltd. |
抗原特異的t細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
EP3270897A4
(en)
|
2015-03-20 |
2018-12-05 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
JP6903046B2
(ja)
|
2015-03-26 |
2021-07-14 |
ジーピーエヌ ワクチン プロプライアタリー リミティド |
連鎖球菌ワクチン
|
BR112017025316A2
(pt)
|
2015-05-26 |
2018-07-31 |
Ohio State Innovation Foundation |
estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL−23−p19ワクチン
|
EP3313439A2
(en)
|
2015-06-26 |
2018-05-02 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
US20180186896A1
(en)
|
2015-07-07 |
2018-07-05 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
KR20230058726A
(ko)
|
2015-07-21 |
2023-05-03 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
CN108431214B
(zh)
|
2015-10-05 |
2022-03-01 |
美国政府(由卫生和人类服务部的部长所代表) |
人轮状病毒g9p[6]毒株和作为疫苗的用途
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2017109698A1
(en)
|
2015-12-22 |
2017-06-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic formulation
|
ES2811523T3
(es)
|
2016-01-19 |
2021-03-12 |
Pfizer |
Vacunas contra el cáncer
|
WO2017137085A1
(en)
|
2016-02-11 |
2017-08-17 |
Sanofi Pasteur |
Meningitidis vaccines comprising subtilinases
|
CA3017356A1
(en)
|
2016-03-10 |
2017-09-14 |
Aperisys, Inc. |
Antigen-binding fusion proteins with modified hsp70 domains
|
US11319383B2
(en)
|
2016-03-14 |
2022-05-03 |
Universitetet | Oslo |
Engineered immunoglobulins with altered FcRn binding
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
KR102392974B1
(ko)
|
2016-05-16 |
2022-05-02 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
Tlr 작용제를 함유하는 제제 및 사용 방법
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
EP3458088A2
(en)
|
2016-05-21 |
2019-03-27 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
JP7140684B2
(ja)
|
2016-06-01 |
2022-09-21 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サイジング剤含有ナノアラム粒子
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
CA3034124A1
(en)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
CN110198735A
(zh)
|
2017-01-20 |
2019-09-03 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
BR112019020209A2
(pt)
|
2017-03-31 |
2020-06-02 |
Glaxosmithkline Intellectual Property Development Limited |
Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação.
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
EP3615005A4
(en)
*
|
2017-04-28 |
2021-03-10 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
VACCINATION COMPOSITIONS AND METHODS
|
CN110996994A
(zh)
|
2017-08-14 |
2020-04-10 |
葛兰素史密丝克莱恩生物有限公司 |
加强免疫应答的方法
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
EP3678699A1
(en)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Vaccine molecules
|
WO2019048928A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
AU2018330165A1
(en)
|
2017-09-08 |
2020-04-02 |
Access To Advanced Health Institute |
Liposomal formulations comprising saponin and methods of use
|
AU2018331874B2
(en)
|
2017-09-13 |
2022-06-02 |
Sanofi Pasteur |
Human cytomegalovirus immunogenic composition
|
WO2019079594A1
(en)
|
2017-10-18 |
2019-04-25 |
The University Of North Carolina At Chapel Hill |
METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
WO2019175145A1
(en)
|
2018-03-12 |
2019-09-19 |
Janssen Vaccines & Prevention B.V. |
Vaccines against urinary tract infections
|
JP2021526831A
(ja)
|
2018-06-12 |
2021-10-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
アデノウイルスポリヌクレオチド及びポリペプチド
|
WO2020030572A1
(en)
|
2018-08-07 |
2020-02-13 |
Glaxosmithkline Biologicals Sa |
Processes and vaccines
|
CA3109889A1
(en)
|
2018-08-23 |
2020-02-27 |
Glaxosmithkline Biologicals Sa |
Immunogenic proteins and compositions
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2020051766A1
(zh)
|
2018-09-11 |
2020-03-19 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
EP3890775A1
(en)
|
2018-12-06 |
2021-10-13 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
TW202102256A
(zh)
|
2019-03-05 |
2021-01-16 |
比利時商葛蘭素史密斯克藍生物品公司 |
B型肝炎免疫法及組合物
|
KR102574882B1
(ko)
|
2019-03-18 |
2023-09-04 |
얀센 파마슈티칼즈, 인코포레이티드 |
대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
|
EP3941516A1
(en)
|
2019-03-18 |
2022-01-26 |
Janssen Pharmaceuticals, Inc. |
Bioconjugates ofe col! o-antigen polysaccharides. methods of production thereof. andmethods of use thereof
|
EP3952906A1
(en)
|
2019-04-10 |
2022-02-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
US20220221455A1
(en)
|
2019-04-18 |
2022-07-14 |
Glaxosmithkline Biologicals Sa |
Antigen binding proteins and assays
|
AU2020325645A1
(en)
|
2019-08-05 |
2022-02-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
JP2022550884A
(ja)
|
2019-10-02 |
2022-12-05 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
スタフィロコッカス(Staphylococcus)ペプチドおよび使用方法
|
US20230000966A1
(en)
|
2019-11-01 |
2023-01-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP4077356A1
(en)
|
2019-12-19 |
2022-10-26 |
GlaxoSmithKline Biologicals SA |
S. aureus antigens and compositions thereof
|
WO2021144369A1
(en)
|
2020-01-16 |
2021-07-22 |
Janssen Pharmaceuticals, Inc. |
Fimh mutant, compositions therewith and use thereof
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
EP4103587A1
(en)
|
2020-02-14 |
2022-12-21 |
Immunor AS |
Corona virus vaccine
|
CA3171864A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
MX2022010350A
(es)
|
2020-02-23 |
2022-09-19 |
Pfizer |
Composiciones de esquerichia coli y sus metodos.
|
EP4114848A4
(en)
|
2020-02-26 |
2024-04-03 |
Versitech Limited |
PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
|
WO2022029024A1
(en)
|
2020-08-03 |
2022-02-10 |
Glaxosmithkline Biologicals Sa |
Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
|
JP7481585B2
(ja)
|
2020-09-17 |
2024-05-10 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
多価ワクチン組成物及びその使用
|
US11225508B1
(en)
|
2020-09-23 |
2022-01-18 |
The University Of North Carolina At Chapel Hill |
Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
|
US20230416309A1
(en)
|
2020-10-23 |
2023-12-28 |
Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji |
Fusion protein and application thereof
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
WO2022101745A2
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
US20240299510A1
(en)
|
2020-12-31 |
2024-09-12 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
IL303954A
(en)
|
2021-01-12 |
2023-08-01 |
Janssen Pharmaceuticals Inc |
FIMH mutants, their compositions and their use
|
WO2022152939A1
(en)
|
2021-01-18 |
2022-07-21 |
Conserv Bioscience Limited |
Coronavirus immunogenic compositions, methods and uses thereof
|
US12053516B2
(en)
|
2021-02-19 |
2024-08-06 |
Sanofi Pasteur Inc. |
Meningococcal B recombinant vaccine
|
WO2022175423A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition, use and methods
|
KR20230164108A
(ko)
|
2021-04-01 |
2023-12-01 |
얀센 파마슈티칼즈, 인코포레이티드 |
E. coli O18 생물접합체의 생산
|
EP4346893A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
CN118434441A
(zh)
|
2021-11-18 |
2024-08-02 |
马特里瓦克斯公司 |
免疫原性融合蛋白组合物和其使用方法
|
AU2023207315A1
(en)
|
2022-01-13 |
2024-06-27 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
WO2024160901A1
(en)
|
2023-02-02 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|